Published in AIDS Weekly, May 5th, 1997
Because this is the first report of an antiviral drug that specifically targets a protein/RNA interaction, the discovery represents a novel pharmaceutical approach to antimicrobial and antitumor agents.
The compound, dubbed CGP64222, was created by a researchers at Novartis Ltd. Pharmaceuticals, Basel, Switzerland, and the Medical Research Council, Cambridge, England.
"CGP64222 is to our knowledge the first example of an antiviral compound that selectively inhibits a protein/RNA interaction," wrote...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.